Moleculin Biotech, Inc. (NASDAQ:MBRX) Forecasted to Earn FY2028 Earnings of $8.88 Per Share

Moleculin Biotech, Inc. (NASDAQ:MBRX) – Equities researchers at Roth Capital issued their FY2028 earnings per share (EPS) estimates for Moleculin Biotech in a report issued on Monday, March 25th. Roth Capital analyst J. Aschoff forecasts that the company will post earnings of $8.88 per share for the year. The consensus estimate for Moleculin Biotech’s current full-year earnings is ($10.27) per share.

A number of other research firms have also weighed in on MBRX. Maxim Group lowered their price objective on Moleculin Biotech from $45.00 to $20.00 and set a “buy” rating on the stock in a research note on Tuesday. StockNews.com began coverage on Moleculin Biotech in a research note on Thursday. They set a “sell” rating on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $45.00 price objective on shares of Moleculin Biotech in a research note on Thursday, December 14th.

Moleculin Biotech Stock Performance

NASDAQ MBRX opened at $5.91 on Wednesday. The stock’s fifty day moving average is $7.83 and its two-hundred day moving average is $8.21. The firm has a market capitalization of $13.18 million, a P/E ratio of -0.43 and a beta of 1.98. Moleculin Biotech has a fifty-two week low of $4.34 and a fifty-two week high of $24.75.

Hedge Funds Weigh In On Moleculin Biotech

Several large investors have recently modified their holdings of the business. State Street Corp lifted its stake in shares of Moleculin Biotech by 19.2% in the 1st quarter. State Street Corp now owns 71,397 shares of the company’s stock valued at $127,000 after purchasing an additional 11,497 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of Moleculin Biotech by 79.3% in the 1st quarter. Renaissance Technologies LLC now owns 59,900 shares of the company’s stock valued at $107,000 after purchasing an additional 26,500 shares during the last quarter. Charles Schwab Investment Management Inc. acquired a new position in shares of Moleculin Biotech in the 4th quarter valued at $39,000. Atticus Wealth Management LLC acquired a new position in shares of Moleculin Biotech in the 4th quarter valued at $43,000. Finally, Citadel Advisors LLC acquired a new position in shares of Moleculin Biotech in the 4th quarter valued at $55,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs.